Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Stevanato Group S.p.A. (NYSE:STVN) has earned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company.

A number of research analysts have issued reports on STVN shares. Morgan Stanley reaffirmed an “equal weight” rating and issued a $23.00 target price (down from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Bank of America lifted their price objective on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Finally, Wolfe Research initiated coverage on Stevanato Group in a report on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price on the stock.

Stevanato Group Price Performance

STVN opened at €23.67 ($24.92) on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group has a 12 month low of €16.56 ($17.43) and a 12 month high of €34.73 ($36.56). The business has a 50 day simple moving average of €19.87 and a 200-day simple moving average of €19.73.

Stevanato Group (NYSE:STVN) last issued its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) EPS for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)). The company had revenue of €277.90 million for the quarter, compared to analysts’ expectations of €274.36 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Stevanato Group’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.16 earnings per share. On average, research analysts anticipate that Stevanato Group will post 0.5 EPS for the current year.

Hedge Funds Weigh In On Stevanato Group

Institutional investors have recently made changes to their positions in the stock. Conestoga Capital Advisors LLC increased its position in Stevanato Group by 5.5% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 7,675,910 shares of the company’s stock worth $153,518,000 after purchasing an additional 400,087 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Stevanato Group by 67.6% in the third quarter. Thrivent Financial for Lutherans now owns 2,784,912 shares of the company’s stock valued at $55,698,000 after buying an additional 1,123,104 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Stevanato Group by 4.5% in the third quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company’s stock valued at $53,872,000 after buying an additional 115,050 shares during the last quarter. Bamco Inc. NY lifted its stake in shares of Stevanato Group by 1.3% during the third quarter. Bamco Inc. NY now owns 1,685,181 shares of the company’s stock valued at $33,704,000 after buying an additional 21,469 shares during the period. Finally, Fred Alger Management LLC boosted its position in Stevanato Group by 24.2% during the third quarter. Fred Alger Management LLC now owns 1,070,557 shares of the company’s stock worth $21,411,000 after acquiring an additional 208,830 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.